Healthcare, Biotech ETFs XLV and XBI Slide on FDA’s Uncertain Outlook
Healthcare companies were among the worst performing stocks Wednesday, with biotechnology sector-specific ETFs taking the brunt of the hit, after…
SBIO
ALPS Medical Breakthroughs ETF
$34.92 $-1.69
(-4.62%)
As of 12:00:00 AM EDT | 3/22/19 | Market Closed
SBIO Trading Data
Open
$36.41
Low Price
$34.91
High Price
$36.41
Previous Last Price
$36.61
Bid Size
$0 X 0
Ask Size
$0 X 0
SBIO Portfolio Data
AUM
$197,560,000
Shares
5,500
PE Ratio
12.55
Price / Book Ratio
3.39
Expense Ratio
0.5
Net Asset Value
$35.92
Volume
Volume
49,100
Avg. Volume (YDT)
43,511
Dollar Volume
$1,442,047
Weekly Avg. Volume
36,060
Monthly Avg. Volume
40,970
Quarterly Avg. Volume
50,543
SBIO Fund Description
The ALPS Medical Breakthroughs ETF invests in the public equity markets of the United States. It invests in the stocks of companies operating in the biotechnology and pharmaceutical sectors. The fund invests in stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the Poliwogg Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.
SBIO Chart
SBIO Summary
Fund Family
ALPS Holdings
Tracks This Index
ALPS Medical Breakthroughs ETF
Inception Date
2015-01-05
Asset Class
Portfolio-Multi Asset
Asset Class Size
Healthcare
SBIO Classification
Region (General)
Global
Region (Specific)
Sector
Health Care
Equity Index
Leveraged Family
SBIO Holdings
Top 10 Holdings
United Therapeutics Corp. (UTHR)
480%
Galapagos NV (GLPG)
451%
Array BioPharma Inc. (ARRY)
448%
Ascendis Pharma AS (ASND)
437%
Agios Pharmaceuticals Inc. (AGIO)
436%
FibroGen Inc. (FGEN)
425%
Immunomedics Inc. (IMMU)
419%
Global Blood Therapeutics Inc. (GBT)
346%
Ligand Pharmaceuticals Inc. (LGND)
321%
Mirati Therapeutics Inc. (MRTX)
314%
Total SBIO Holdings
Total Holdings: 72
United Therapeutics Corp. (UTHR)
480%
Galapagos NV (GLPG)
451%
Array BioPharma Inc. (ARRY)
448%
Ascendis Pharma AS (ASND)
437%
Agios Pharmaceuticals Inc. (AGIO)
436%
FibroGen Inc. (FGEN)
425%
Immunomedics Inc. (IMMU)
419%
Global Blood Therapeutics Inc. (GBT)
346%
Ligand Pharmaceuticals Inc. (LGND)
321%
Mirati Therapeutics Inc. (MRTX)
314%
Emergent BioSolutions Inc. (EBS)
311%
uniQure NV (QURE)
295%
Acceleron Pharma Inc. (XLRN)
286%
Halozyme Therapeutics Inc. (HALO)
283%
Insmed Inc. (INSM)
275%
PTC Therapeutics Inc. (PTCT)
272%
Arena Pharmaceuticals Inc. (ARNA)
269%
Madrigal Pharmaceuticals Inc. (MDGL)
260%
AnaptysBio Inc. (ANAB)
240%
Enanta Pharmaceuticals Inc. (ENTA)
233%
CRISPR Therapeutics AG (CRSP)
232%
Atara Biotherapeutics Inc. (ATRA)
215%
Apellis Pharmaceuticals Inc. (APLS)
134%
Fate Therapeutics Inc. (FATE)
131%
Rhythm Pharmaceuticals Inc. (RYTM)
130%
Akebia Therapeutics Inc. (AKBA)
123%
MacroGenics Inc. (MGNX)
116%
Vericel Corp. (VCEL)
99%
Cara Therapeutics Inc. (CARA)
91%
UroGen Pharma Ltd. (URGN)
88%
Acorda Therapeutics Inc. (ACOR)
79%
Viking Therapeutics Inc. (VKTX)
74%
Voyager Therapeutics Inc. (VYGR)
74%
NuCana PLC (NCNA)
73%
Kura Oncology Inc. (KURA)
71%
GlycoMimetics Inc. (GLYC)
70%
ChemoCentryx Inc. (CCXI)
69%
G1 Therapeutics Inc. (GTHX)
67%
ArQule Inc. (ARQL)
66%
PDL BioPharma Inc. (PDLI)
66%
Flexion Therapeutics Inc. (FLXN)
60%
Five Prime Therapeutics Inc. (FPRX)
58%
Corbus Pharmaceuticals Holdings Inc. (CRBP)
56%
AMAG Pharmaceuticals Inc. (AMAG)
53%
Catalyst Pharmaceuticals Inc. (CPRX)
52%
Achillion Pharmaceuticals Inc. (ACHN)
51%
Progenics Pharmaceuticals Inc. (PGNX)
46%
Concert Pharmaceuticals Inc. (CNCE)
46%
Krystal Biotech Inc. (KRYS)
45%
Abeona Therapeutics Inc. (ABEO)
45%
ImmunoGen Inc. (IMGN)
45%
Albireo Pharma Inc. (ALBO)
43%
MediciNova Inc. (MNOV)
42%
AC Immune SA (ACIU)
40%
Syros Pharmaceuticals Inc. (SYRS)
39%
CASI Pharmaceuticals Inc. (CASI)
37%
Minerva Neurosciences Inc. (NERV)
37%
Kiniksa Pharmaceuticals Ltd. (KNSA)
37%
Aduro Biotech Inc. (ADRO)
37%
Savara Inc. (SVRA)
35%
Xenon Pharmaceuticals Inc. (XENE)
31%
Calithera Biosciences Inc. (CALA)
31%
Tocagen Inc. (TOCA)
30%
MEI Pharma Inc. (MEIP)
27%
Athersys Inc. (ATHX)
27%
Adamas Pharmaceuticals Inc. (ADMS)
26%
Arbutus Biopharma Corp. (ABUS)
25%
Synlogic Inc. (SYBX)
24%
State Street Institutional Treasury Plus Money Market Fund (TPIXX)
5%
Cash and Equivalents
1%
ALPS Medical Breakthroughs ETF (SBIO)
0%
Corium International Inc (CORI-CVR)
0%
SBIO Technicals
Alpha
-8.64
Beta
1.69
Leverage
Long
Standard Deviation
3.01
SBIO Dividends
Dividend Date
2018-12-20
Latest Dividend
0.784
Annual Dividend
0.78
Annual Dividend Rate
0.78
Annual Dividend Yield
2.18
SBIO Performance
YTD Return
24.09%
1 Year Return
-0.26%
3 Year Return
67.4%
5 Year Return
0%
10 Year Return
40.58%
SBIO Related Articles
Spark Therapeutics Acquisition Sparks Rally in Biotechnology ETFs
Biotechnology stocks and sector-specific ETFs climbed Monday after Roche (RHHBY) acquired gene therapy researcher Spark Therapeutics (ONCE). Among the best…
Biotech ETFs Surge After Eli Lilly Buys Out Loxo Oncology
Biotechnology stocks and sector-related ETFs were among the best performers Monday after Eli Lilly (NYSE: LLY) said it will acquire…
6 Top Healthcare ETFs Rally as Trump Vows End to ‘Global Freeloading’
Healthcare stocks and top healthcare ETFs rallied Friday after President Donald Trump vowed to end to “global freeloading” that has…
A Nifty Biotech ETF Idea for 2018
Biotechnology stocks bolstered the broader healthcare sector last year, a theme that is expected to continue in 2018. Investors looking…
Biotech ETFs Jump on Gilead, Kite Deal
The biotechnology segment rallied Monday with small-cap biotech names and related exchange traded funds leading the charge after Gilead Sciences…